Longitudinal analysis of the in vitro activity profile of oritavancin and comparator glycopeptides against Gram-positive organisms from Europe: 2005-2008.

Methods: In total 2072, recent (2005-2008) clinical isolates of S. aureus (SA; n = 757), coagulase-negative staphylococci (CoNS; n = 346), Enterococcus spp. (EN; n = 501), S. pyogenes (GAS; n = 241), and S. agalactiae (GBS; n = 227) from 52 hospital sites in EU (17 countries) were centrally tested by broth microdilution (CLSI; M7-A7) against ORI, teicoplanin (TEI), and vancomycin (VAN). ORI assays included 0.002% polysorbate-80 throughout.